Trial Profile
Pilot study of rituximab treatment to inhibit HLA [human leukocyte antigen] antibodies in renal allograft recipients
Status:
Withdrawn prior to enrolment
Phase of Trial:
Phase I/II
Latest Information Update: 26 Oct 2023
Price :
$35
*
At a glance
- Drugs Rituximab (Primary)
- Indications Renal transplant rejection
- Focus Pharmacodynamics
- 20 Oct 2023 Status has been changed to withdrawn prior to enrolment.
- 07 Jul 2007 New trial record.